Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Phenomenex Chiral Screening Services Now Offered in China

Published: Wednesday, December 05, 2012
Last Updated: Wednesday, December 05, 2012
Bookmark and Share
Collaboration with Chinese Academy of Sciences ensures Fast, high-quality Screening.

Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, announces the extension of its Chiral Screening Service to pharmaceutical and natural products customers in China.
PHenomenexChiralSvsChina.gif
The service is offered in collaboration with the Chinese Academy of Sciences (CAS), a leading academic and R&D center under which the Shanghai Institute of Organic Chemistry (SIOC) has developed a strong chiral team that works closely with Phenomenex. The free Chiral Screening Service provides target screening using a library of HPLC columns including the Phenomenex Lux™ polysaccharide-based offerings, which demonstrate a success rate approaching 90 percent. After resolving the chiral compound, Phenomenex delivers a method development and optimization plan to the customer within 10 business days – the same rapid turnaround the service promises in the U.S. and Europe.

“Our customer base in China has been growing rapidly and the expansion of our services will help us better serve them,” explains Michael Klein, brand manager for Phenomenex. “By teaming up with the CAS-SIOC, we are able to quickly roll out our rapid-response service.”

Enantiomers of chiral compounds may have different pharmacological effects in biological systems and they must be identified and evaluated separately. “Resolving chiral compounds is relatively difficult, and column selection can be complicated,” continues Klein. “Our Chiral Screening Service eliminates time-consuming guesswork and also gives customers a chance to ‘test-drive’ our Lux columns.”

The Phenomenex team of chiral experts will customize a plan for each screening project, taking into account specific requirements and overall separation goals. Once a project is completed, the customer will receive a report that details the optimal method including information on the chiral stationary phase (CSP) selected for the separation, running conditions and associated chromatograms. Customers can find more information at: http://www.phenomenex.com/chromatographyservices or contact the group directly via e-mail at chromservices@phenomenex.com.

Phenomenex, celebrating its 30th anniversary in 2012, is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical research, government and academic laboratories. From drug discovery and pharmaceutical development to food safety and environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being.  For more information on Phenomenex, visit www.phenomenex.com.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Phenomenex Launches Innovative, Industry-Focused Websites
Company builds on award-winning web presence with new digital experience.
Friday, February 22, 2013
Phenomenex and USP Offer Workshop on Practical Application of Chapter <621>
Half-Day Course at Pittcon Will Help Labs Develop Method Adjustments for Greater Stability and Productivity
Monday, February 15, 2010
Phenomenex Introduces www.strataSPE.com: Interactive Solutions for Sample Preparation
This website contains the latest information on SPE products, techniques, applications, and method development.
Thursday, April 13, 2006
Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!